Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–46. https://doi.org/10.1093/eurheartj/ehac361.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsimikas S, Marcovina SM. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;80(9):934–46. https://doi.org/10.1016/j.jacc.2022.06.019.

Article  CAS  PubMed  Google Scholar 

Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, Gabrielli D, Oliva F, Imperoli G, Colivicchi F. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart. 2022;109(1):18–25. https://doi.org/10.1136/heartjnl-2021-320708.

Article  CAS  PubMed  Google Scholar 

Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiol Ther. 2024;13(1):39–67. https://doi.org/10.1007/s40119-024-00353-w. 

Article  PubMed  PubMed Central  Google Scholar 

Tsamoulis D, Kosmas CE, Rallidis LS. Is inverse association between lipoprotein(a) and diabetes mellitus another paradox in cardiometabolic medicine? Expert Rev Endocrinol Metab. 2024;19(1):63–70. https://doi.org/10.1080/17446651.2023.2293108.

Article  CAS  PubMed  Google Scholar 

•• Lamina C, Ward NC. Lipoprotein (a) and diabetes mellitus. Atherosclerosis. 2022 ;349:63–71. https://doi.org/10.1016/j.atherosclerosis.2022.04.016. (This review aims to shed light on the most recent findings of epidemiological and Mendelian Randomisation studies regarding the inverse association between Lp(a) and risk of prevalent and incident diabetes.)

Di Fusco SA, Maggioni AP, Scicchitano P, Zuin M, D’Elia E, Colivicchi F. Lipoprotein (a), Inflammation, and Atherosclerosis. J Clin Med. 2023;12(7):2529. https://doi.org/10.3390/jcm12072529.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526–37. https://doi.org/10.1194/jlr.R061648.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kraft HG, Lingenhel A, Köchl S, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16(6):713–9. https://doi.org/10.1161/01.atv.16.6.713.

Article  CAS  PubMed  Google Scholar 

Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160–7. https://doi.org/10.1016/j.jacc.2009.10.080.

Article  CAS  PubMed  Google Scholar 

Lamina C. Mendelian Randomization: Principles and its usage in Lp(a) research. Atherosclerosis. 2022;349:36–41. https://doi.org/10.1016/j.atherosclerosis.2022.04.013.

Article  CAS  PubMed  Google Scholar 

Wang S, Zha L, Chen J, Du D, Liu D, Zhong M, Shang R, Sun D, Sun C, Jin E. The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis. Eur J Med Res. 2022;27(1):211. https://doi.org/10.1186/s40001-022-00825-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Kronenberg F. Lipoprotein(a): from Causality to Treatment. Curr Atheroscler Rep. 2024;26(3):75–82. https://doi.org/10.1007/s11883-024-01187-6 (This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease and how high Lp(a) concentrations should be managed now and with an outlook to the future.)

Mukamel RE, Handsaker RE, Sherman MA, Barton AR, Zheng Y, McCarroll SA, Loh PR. Protein-coding repeat polymorphisms strongly shape diverse human phenotypes. Science. 2021;373(6562):1499–505. https://doi.org/10.1126/science.abg8289.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S, Willeit P. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16:38.

Article  PubMed  PubMed Central  Google Scholar 

Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021;42:1147–56.

Article  CAS  PubMed  Google Scholar 

Skoumas I, Andrikou I, Grigoriou K, Dima I, Lazarou E, Vlachopoulos C, Tsioufis K. Lipoprotein(a), metabolic profile and new-onset type-2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study. J Clin Lipidol. 2023;17(4):512–8. https://doi.org/10.1016/j.jacl.2023.05.103.

Article  PubMed  Google Scholar 

Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013;1(3):220–7. https://doi.org/10.1016/S2213-8587(13)70064-0.

Article  CAS  PubMed  Google Scholar 

Tolbus A, Mortensen MB, Nielsen SF, Kamstrup PR, Bojesen SE, Nordestgaard BG. Kringle IV Type 2, Not Low Lipoprotein(a), as a Cause of Diabetes: A Novel Genetic Approach Using SNPs Associated Selectively with Lipoprotein(a) Concentrations or with Kringle IV Type 2 Repeats. Clin Chem. 2017;63(12):1866–76. https://doi.org/10.1373/clinchem.2017.277103.

Article  CAS  PubMed  Google Scholar 

Kostner KM, Kostner GM. The 10 essential questions regarding lipoprotein(a). Curr Opin Clin Nutr Metab Care. 2024;27(2):136–43. https://doi.org/10.1097/MCO.0000000000000994.

Article  CAS  PubMed  Google Scholar 

•• Ward NC, Vickneswaran S, Watts GF. Lipoprotein (a) and diabetes mellitus: causes and consequences. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):181–187. https://doi.org/10.1097/MED.0000000000000597. (This review provides an update on the role of lipoprotein (a) [Lp(a)] in diabetes, including its impact as a risk factor as well as its contribution to the development of cardiovascular disease.)

Li M, Wang Y, Yao Q, Liang Q, Zhang Y, Wang X, Li Q, Qiang W, Yang J, Shi B, He M. Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2024;15(14):1337469. https://doi.org/10.3389/fendo.2023.1337469.

Article  Google Scholar 

GholamiChahkand MS, EsmaeilpourMoallem F, Qezelgachi A, Seifouri K, PesaranAfsharian A, Sheikhzadeh F, Poursalehi A, FaniSadrabadi FS, SaghabTorbati M, Ramezanzade M, Alishiri G, Ansari A, ZareDehabadi E, KarimiMatloub S, Sheikh Z, Deravi N, Mehrtabar S, Chichagi F, FaalHamedanchi N, Arzaghi M, Asadi M, AlsadatDadkhah P, Ansari A. Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review. Diab Vasc Dis Res. 2023;20(6):14791641231197114. https://doi.org/10.1177/14791641231197114.

Article  CAS  Google Scholar 

Wang P, Yuan D, Zhang C, Jia S, Song Y, Tang X, Zhao X, Gao R, Xu B, Yuan J. Association between cumulative lipoprotein(a) exposure and adverse cardiovascular outcomes in patients with prediabetes or diabetes. iscience. 2023;26(3):106117. https://doi.org/10.1016/j.isci.2023.106117.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi Q, Qi L. Lipoprotein(a) and cardiovascular disease in diabetic patients. Clin Lipidol. 2012;7(4):397–407. https://doi.org/10.2217/clp.12.46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Littmann K, Wodaje T, Alvarsson M, Bottai M, Eriksson M, Parini P, Brinck J. The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. Diabetes Care. 2020;43(8):1851–8. https://doi.org/10.2337/dc19-1398.

Article  CAS  PubMed  Google Scholar 

• Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiol Ther. 2024 Mar;13(1):39–67. https://doi.org/10.1007/s40119-024-00353-w. (This comprehensive review, provide a detailed overview of RNA-based therapeutic approaches and discuss the recent advances and challenges of RNA therapeutics specifically designed to reduce Lp(a) levels and thus the risk of cardiovascular disease.)

Schmidt AM. Diabetes Mellitus and Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019;39(4):558–68. https://doi.org/10.1161/ATVBAHA.119.310961.

Article  CAS  PubMed  PubMed Central  Google Scholar